# TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

> **NCT04518345** · EARLY_PHASE1 · COMPLETED · sponsor: **Uma Borate** · enrollment: 3 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Therapy-Related Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Dubermatinib

## Key facts

- **NCT ID:** NCT04518345
- **Lead sponsor:** Uma Borate
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2021-10-13
- **Final completion:** 2021-12-22
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04518345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04518345, "TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04518345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*